The role of mini-bronchoalveolar lavage fluid in the diagnosis of pulmonary tuberculosis in critically ill patients

Cynthia Pessoa Neves, Allyson Guimarães Costa, Izabella Picinin Safe, Alexandra de Souza Brito, Jaquelane Silva Jesus, Afranio Lineu Kritski, Marcus Vinicius Guimarães Lacerda, Miguel Viveiros and Marcelo Cordeiro-Santos

Abstract

Background: The detection of Mycobacterium tuberculosis (MTB) in the intensive care unit (ICU) presents several challenges, mainly associated to the clinical state of the patient. The presence of HIV infection further aggravates this scenario, requiring a reliable collection method, with better performance in the microbiological/molecular techniques to be used. We evaluated the performance of two methods for sample collection, mini bronchoalveolar lavage (Mini-BAL) and endotracheal aspirate (ETA), for diagnosis of pulmonary tuberculosis (PTB) in critically ill patients.

Methods: This prospective study involved 26 HIV positive ICU internalized patients, with presumptive PTB who required mechanical ventilation. Two samples were obtained prospectively from 26 HIV ICU patients with presumptive PTB by Mini-BAL and ETA. The samples were processed for smear microscopy, Löwenstein-Jensen medium and the BACTEC Mycobacteria Growth Indicator Tube 960 system. We define as confirmed PTB patients with positive MTB culture. Furthermore, all samples obtained through the Mini-BAL were analyzed by Xpert® MTB/RIF.

Results: Our results demonstrated that the respiratory samples obtained by Mini-BAL were able to increase MTB detection in critically ill patients with presumptive PTB. The Mini-BAL allowed 30% increased recovery and guaranteed enough sample volume for processing in all methods. In addition, the larger volume of the samples obtained with this technique enabled the Xpert® MTB/RIF molecular test for diagnosis of TB.

Conclusions: The Mini-BAL showed be an acceptable alternative to ETA in this population, since these critically ill and often-immunocompromised patients are more likely to develop complications related to invasive procedures.

Keywords: Pulmonary tuberculosis, Intensive care medicine, Diagnosis, Mini-BAL
Background

An increasing proportion (3–16%) of patients diagnosed with active tuberculosis (TB) require intensive care [1–3]. In countries with high TB and human immunodeficiency virus (HIV) burden [i.e. Brazil], TB/HIV co-infection accounts between 69 and 93% of TB cases admitted at an intensive care unit (ICU), usually associated with acute respiratory failure (ARF) and mechanical ventilation (MV) [3, 4]. Patients with TB admitted to the ICU have a poor prognosis and are associated with increasing costs for the health system when compared to a patient with uncomplicated TB [5, 6].

The diagnosis of pulmonary tuberculosis (PTB) in ICU settings presents challenges, mainly to obtain fast and reliable microbiological confirmation. In people living with HIV (PLWH) and critically ill patients, the diagnosis of TB may be more difficult due to the greater frequency of paucibacillary forms in advanced stages of immunodepression and develop complications related to invasive procedures [7].

Microbiological sampling from a mechanically ventilated patient will require an endotracheal aspirate (ETA), a non-directed bronchial lavage or a bronchoalveolar lavage (BAL) [7]. Although it is an easy-to-perform, low-cost and non-invasive method, the ETA has several limitations, such as low specificity and high false positive rates for the diagnosis of pulmonary infections [8].

The bronchoscopic procedures (i.e. BAL) are expensive, require qualified human resources, suitable devices (e.g. size of the bronchoscope according to the size of endotracheal tube); and it requires care with operationalization, monitoring and decontamination of equipment. Furthermore, is unavailable in many HIV and TB endemic settings [9, 10]. In addition, the BAL has been associated with several complications in patients receiving MV, especially with acute respiratory distress syndrome. Other related complications are hypoxemia, pneumothorax, cardiac arrhythmias and bleedings. Therefore, the risks/benefits of BAL should be carefully considered in the critical patient scenario prior to the application, using the technique when less invasive methods presents limitations or are not effective for diagnosis [10].

Critically ill patients are more likely to develop complications related to invasive procedures. Therefore, it is necessary that less invasive diagnostic strategies be used instead of BAL. An alternative method for obtaining respiratory samples in mechanically ventilated patients is the mini bronchoalveolar lavage (Mini-BAL); a simple, less invasive and low-cost method. It is defined as a blind and sterile technique for collection of the lower respiratory specimen by a tracheal tube (50 cm) and instillation of saline solution. The amount of instilled solution may range from 20 to 150 ml. However, small amounts of fluid (e.g. 20 ml) are commonly used [11].

Mini-BAL was first used successfully in 1987 for the diagnosis of opportunistic infection in AIDS patients [12]. It is a simple, less invasive and low-cost method. Since then, it has been used for diagnosis and prognosis of lung injury and related pulmonary diseases, including immunocompromised patients [9, 13, 14]. However, to date it has not been studied whether the Mini-BAL would be useful for the diagnosis of PTB in critically ill patients. In this study, we evaluated the performance of two methods for sample collection, Mini-BAL and ETA, for presumptive PTB critically ill patient’s diagnosis at a referral hospital for TB in PLWH located in the Brazilian Amazon.

Methods

Ethical issue and study population

This study was approved by the Ethics Committee at Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (CEP/FMT-HVD #process: 1.531.521/2016). Signed informed consent was obtained from each participant or legal representative for the use of biological materials and publication of data. All procedures are in accordance with the Resolution 466/12 from the Brazilian Ministry of Healthy and also with the Helsinki Declaration.

This prospective study (October 2016 and July 2017) involved 53 ICU internalized patients (>18 years old), with presumptive PTB diagnosis who required MV at FMT-HVD (Fig. 1). Twenty-seven individuals were excluded for presenting complications that prevented the accomplishment of the procedures (ETA and Mini-BAL) and/or were already undergoing treatment for PTB for more than 2 weeks.

Before procedure of the collection, all vital signs were monitored, inspiratory fraction of O2 was increased to 1.0 and sedation was maintained with bolus of 3-5 mg intravenous midazolam.

Sample collection randomization

Sample collection was performed using the ETA and Mini-BAL methods. Two samples were obtained from each patient and the order of collection techniques performed was randomized using the website Random [https://www.random.org/]. Briefly, List Randomizer function was used, which randomized the method of the according with list provided.

ETA sample collection

ETA collection was performed using a sterile suction catheter of size 12 French (Fr) introduced through the endotracheal tube (ET) until resistance was encountered (level of the carina in the trachea), retracted approximately 2 cm and sample collected in a sterile container by suction. The samples were aspirated into a
sterile polypropylene collector tube (bronco collector; Cremer®, Brazil).

**Mini-BAL sample collection**

The Mini-BAL collection was performed by a sterile long suction catheter of size 12 French (Fr) inserted through the ET and blindly advanced into the distal airways till resistance is felt then the catheter was wedged in that position. 20 ml of Sodium Chloride 0.9% were instilled through the catheter and aspirate was collected in a sterile polypropylene collector tube (bronco collector; Cremer®, Brazil) container by suction [11]. After these proceedings, the probe was delicately removed using turning movements.

**Sample transport and microbiology processing**

All the samples were transported to TB Laboratory at FMT-HVD within 30 min of collection. The specimens were processed according to standard sample treatment procedures to smear microscopy, liquid and solid culture [15]. Furthermore, all samples obtained through the Mini-BAL were analyzed by the molecular test Xpert® MTB/RIF (Fig. 1).

**Liquid and solid culture test**

The liquid and solid culture were performed with respiratory specimens digested and decontaminated using the N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) method [16]. Liquid culture tubes (Mycobacteria Growth Indicator Tube - MGIT) were incubated at 37°C in the BD BACTEC MGIT 960 system® [Becton Dickinson, Franklin Lakes, NJ, USA]) instrument and monitored automatically. The solid culture tubes (Löwenstein-Jensen [LJ] medium) were incubated at 37°C and were inspected once weekly or until *Mycobacterium* colonies were seen. The tubes were maintained until it became positive or for 42 days of maximum for negative samples. All the positive tubes were further confirmed by Ziehl–Neelsen (ZN) staining method and further confirmed by MPT64 protein specific detection immune
chromatographic test (SD Bioline Kit, Standard Diagnostics, Inc., Korea) [15].

**Molecular test Xpert® MTB/RIF**
Molecular test Xpert® MTB/RIF was performed with respiratory specimens digested and decontaminated using the NALC-NaOH method [16]. The specimens were processed on the day of collection and 1 mL was tested in an Xpert® MTB/RIF cartridge-based. Rapid molecular assays were performed in GeneXpert® System (Cepheid, Sunnyvale, CA, USA) and all GeneXpert® protocols were provided by Cepheid company.

**Diagnosis of PTB**
Case definition of PTB was used the following criteria: person with presumptive severe TB and growth MTB in MGIT or solid LJ culture in at least one sample obtained by Mini-BAL or ETA.

**Statistical analysis**
Data were stored in the Microsoft Excel software (v.2010) and statistically analyzed using the GraphPad Prism (v.5, San Diego, CA, USA). Descriptive analysis was performed using number (n) and percent (%) for qualitative data and median and IQR for quantitative data. Statistical Analysis were assembled to Chi-squared test was used to study association between qualitative variables and comparison between groups was performed using Mann-Whitney Test for quantitative variables. Statistical difference was considered in all cases at \( p < 0.05 \).

**Results**
**Patients demographic and clinical data**
Table 1 summarizes of the patient’s demographic and clinical data. Of the total 26 patients included, five patients the ETA was not performed due to insufficient volume for the diagnostic tests (< 1 mL), smaller than optimal volume (5-10 mL) for liquid and solid culture, beyond the Xpert® MTB/RIF. In addition, all Mini-BAL samples could be processed, significantly number higher than by ETA \( (p = 0.018) \). The median age was 35 years (IQR: 29–46), with a predominance of male (73%). 92% of the patients were HIV+, 46% were treated for PTB and 23% evolved to death (clinical outcome). The hypoxemia was observed with ETA and Mini-BAL procedures respectively in 3 (11.5%) and in 2 (7.7%) patients (data not shown).

**Volume recovery in mini-BAL was superior of the ETA**
The medium sample volume was 3 mL (IQR: 2–5) for ETA and 10 mL (IQR: 6–11) for Mini-BAL \( (p < 0.0001) \). The Mini-BAL allowed 30% increased recovery and guaranteed sufficient sample volume for processing in all methods (Fig. 2).

**Comparison between mini-BAL and EDTA collection for diagnosis PTB**
The MTB was identified in 3 (14%) and 5 (19%) samples of ETA and Mini-BAL \( (p = 0.653) \), respectively (Table 2). Five confirmed TB cases were observed. Two samples contaminated in solid culture with LJ medium in both techniques. ETA failed to detect TB in solid culture in two samples. Also, cases of false positive or negative in smear microscopy/MGIT/culture of ETA was identified, with one sample detected only in microscopy of ETA sample. Moreover, 5 samples obtained with the Mini-BAL had the diagnosis for MTB confirmed by the molecular method Xpert® MTB/RIF (Table 2). Furthermore, the mean time to detection (TTD) of the mini-BAL samples in the MGIT system was lower (8.2 days) but was not significantly different from the TTD of the ETA (9.0 days) \( (p = 0.134) \) (data not shown).

| Table 1 Demographic and clinical data of the of the ICU internalized patients enrolled in study |
|-----------------------------------------------|
| **Demographic and Clinical Data** | ETA<sup>a</sup> \( (n = 26) \) | Mini-BAL<sup>b</sup> \( (n = 26) \) |
| Age (years, median [IQR]) | 35 [29–46] | |
| Sex, (male/female) | 19/7 | |
| HIV+, n (%) | 24 (92) | |
| TB-treatment, n (%) | 12 (46) | |
| Outcome (death), n (%) | 6 (23) | |
| Gold-Standard Eligible Samples, n (%) | 21<sup>c</sup> (81) | 26 (100) |

<sup>a</sup>Endotracheal Aspirate; <sup>b</sup>Mini bronchoalveolar lavage; <sup>c</sup>5 samples of ETA had volume < 1 ml

**Fig. 2** Median of Volume recovery in Mini-BAL and ETA of the ICU internalized patients
Table 2 Results of diagnosis methods used for presumptive PTB in critically ill patients of the ICU internalized

| Diagnosis Methods Description | Collection Techniques | ETA (n = 21) | mini-BAL (n = 26) | P value |
|------------------------------|-----------------------|-------------|------------------|--------|
| Smear microscopy-positive, n (%) | 6 (29) | 5 (19) | 0.451 |
| Culture MGIT-positive, n (%) | 4 (21) | 5 (19) | 0.987 |
| Culture LJ-positive, n (%) | 3 (16) | 5 (19) | 0.653 |
| Xpert MTB/RIF®-positive, n (%) | – | 5 (19) | – |

*5 samples of ETA had volume < 1 ml

Discussion

The detection of MTB in the ICU presents several challenges, mainly associated to the clinical state of the patient. The presence of HIV infection further aggravates this scenario, requiring a reliable collection method, with better performance in the microbiological/molecular techniques to be performed. The diagnosis of TB in HIV infected individuals may be more difficult due to the greater frequency of paucibacillary forms in advanced stages of immunodepression [9, 10]. Our results demonstrated that the Mini-BAL proved to be a viable alternative, since these critically ill and often immunocompromised patients are more likely to develop complications related to invasive procedures.

Patients with TB required ICU care in worldwide, may have high rates of co-morbidities related complications this site. In other ICU patients, diagnostic of TB may be an incidental co-morbid finding as previously undiagnosed sub clinical disease which only manifests during hospitalization [6, 17]. Mortality is high for patients with active TB and respiratory failure, mainly associated with delay in the TB diagnosis. As shown in our report (23%), other studies have shown similar data, ranging between 25 and 65% mortality [4, 18].

ICU patients present particularities, especially in cases presumptive PTB critical ill [6]. The sampling collections with ETA technique in these patients may sometimes be restricted by persistent severe hypoxemia or cardiovascular instability, presence of small endotracheal tubes and/or the unavailability of a bronchoscopist [14]. Thus, the diagnosis of cases presumptive PTB critical with Mini-BAL seems to be a viable alternative, since this method is less-invasive, easily performed at the bedside method and offering quality samples for microbiological identification, especially in middle- and low-income countries.

Although insufficient data regarding the utility of Mini-BAL to TB diagnosis, some studies have applied the technique for the diagnosis of ventilator-associated pneumonia, including in immunocompromised patients [9, 19–22]. In addition, Mini-BAL was used for the bio marker identification in patients with lung injury [13], evaluated inflammation in patients with acute hypoxemic respiratory failure [14], cytological diagnosis of interstitial disorders with ARF and MV [23], concentration and absorption of antibiotics [24] and the safety and diagnostic accuracy of transbronchial biopsy [25]. Possible complications such as hypoxemia, arrhythmia and bleeding were also evaluated in each technique.

In our study, Mini-BAL allowing the recovery of median 10 mL of respiratory sample (IQR 5-10 mL), significantly more than the volume recovered (p < 0.0001), with non-inferior results to ETA for MTB detection. In addition, the larger volume of the samples obtained with the Mini-BAL (10 mL) enabled the Xpert® MTB/RIF molecular test for diagnosis of TB. An adequate sample volume may be critical for the diagnosis of TB. For example, a sample volume of 6 mL or more of cerebrospinal fluid (CSF) was associated with higher MTB detection in patients with suspected tuberculous meningitis using Xpert® MTB/RIF Ultra or solid culture as a diagnostic method [26]. For PTB, greater sputum volume may have a positive impact on detection of *Mycobacterium tuberculosis* by Xpert® MTB/RIF in smear-negative patients [27].

According to Practice Guideline for clinical microbiology laboratories that addresses requirements pertaining to laboratory testing for mycobacteria and aspects of acceptable specimens and rejection criteria, an optimal volume for samples of the respiratory tract between 5 and 10 mL is recommended [28]. Therefore, 7 (27%) ETA samples were considered inadequate because they presented insufficient volume (< 5 ml) and five (19%) ETA samples were excluded to insufficient volume for the diagnostic tests (Table 1).

To our knowledge, this is the first study to show that samples obtained by the Mini-BAL are viable for the molecular diagnosis of TB (i.e. Xpert® MTB/RIF) in critically ill patients. All samples obtained by the Mini-BAL could be processed in the Xpert machine, without occurrence of errors or indeterminate results.

Our study is limited due to small sample size. However, the techniques were randomized in each patient to mitigate possible bias, may become the Mini-BAL an acceptable alternative to tracheal aspiration for the evaluation of suspected tuberculosis in critically ill patients admitted at an intensive care unit (ICU).

Conclusion

In summary, Mini-BAL presented similar results for the diagnosis of PTB when compared to ETA. Furthermore, respiratory samples obtained by Mini-BAL were able to be tested for *M. tuberculosis* detection, as well as, greater recovery of specimens, in critically ill patients with presumptive PTB, showing an acceptable alternative to ETA in this population. Future research is needed to validate these results, establish their general applicability, and determine the influence of the laboratorial diagnostic in clinic and patient follow-up.
Abbreviations
ARF: Acute respiratory failure; ETA: Endotracheal aspirate; HIV: Human immunodeficiency virus; ICU: Intensive care unit; LJ: Lowenstein; MGIT: Mycobacteria growth indicator tube; Mini-BAL: Mini-bronchoalveolar lavage; MTB: Mycobacterium tuberculosis; MV: Mechanical ventilation; PTB: Pulmonary tuberculosis; TB: Tuberculosis; TTD: Time to detection.

Acknowledgments
The authors acknowledge the support of the staff of the ICU and the Mycobacteria laboratory of FMT-HVD.

Authors’ contributions
CPN, IPS and ASB collected the sample and clinical data and followed the patients. CPN and JSJ coordinated the laboratory work and procedures. CPN, ASB, AGC and MCS participated in the analysis and interpretation of data and drafting the manuscript. AGC, ALK, MVGL, MV and MCS conceived the study and participated in its design, coordination and revising the manuscript. All authors read and approved the final manuscript.

Availability of data and materials
The data sets generated during the current study are available from the corresponding author on reasonable request.

Funding
This work was funded by Brazilian Ministry of Health (Amazonas Interfederative Cooperation), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) (Pró-Estado Program - #002/2008 and PAPAC Program - #005/2019) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes). ALK and MVGL are CNPq fellows. ASB and IPS (PhD students) have fellowship from CAPES. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethics approval and consent to participate
This project was approved by Ethical Committee from Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (CEP/FMT-HVD #process: 1.531.521/2016), according to Declaration of Helsinki and Resolution 466/12 of the Brazilian National Health Council for research involving human subjects. All participants gave consent and signed the form.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil. 2Instituto de Pesquisa Clínica Carlos Chagas, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), Manaus, AM, Brazil. 3Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil. 4Programa de Pós-Graduação em Imunologia Básica e Aplicada, Universidade Federal do Amazonas (UFAM), Manaus, AM, Brazil. 5Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Manaus, AM, Brazil. 6Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisbon, Portugal.

Received: 13 November 2019 Accepted: 9 March 2020
Published online: 18 March 2020

References
1. Loh WJ, Yu Y, Loo CM, Low SY. Factors associated with mortality among patients with active pulmonary tuberculosis requiring intensive care. Singap Med J. 2017;58:656–9.
2. Calligaro GL, Theron G, Khailey H, Peter J, Meldau R, Matinyenya B, et al. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden. Lancet Respir Med. 2015;3:621–30.
3. Ferreira MD, CPD N, Souza AB, Beraldi-Magalhães F, Miglioli GB, Kritski AL, et al. Predictors of mortality among intensive care unit patients infected with tuberculosis and HIV. J Bras Pneumol. 2018;44:118–24.
4. Silva DR, Menegotto DM, Schultz LF, Gazzana MB, Dalcin PT. Mortality among patients with tuberculosis requiring intensive care: a retrospective cohort study. BMC Infect Dis. 2010;10:554.
5. Hagan G, Nathani C. Clinical review: tuberculosis on the intensive care unit. Crit Care. 2013;17:240.
6. Otu A, Hashimi M, Mukhtar AM, Kwizera A, Tiberi S, Macrae B, et al. The critically ill patient with tuberculosis in intensive care: clinical presentations, management and infection control. J Crit Care. 2018;45:184–96.
7. Passi NN, Buckley J. Tuberculosis on the intensive care unit. Br J Hosp Med. 2013;79:1–10.
8. Torres A, Martins A, Puig de la Bellacasa J, Ferrer M, El-Ebiary M, Gonzalez J, et al. Specificity of endotracheal aspiration, protected specimen brush, and bronchoalveolar lavage in mechanically ventilated patients. Am Rev Respir Dis. 1993;147:952–7.
9. Tabaskan MS, Gurgun A, Basoglu OK, Elkken PK, Pullukcu H, Bacakoglu F. Comparison of bronchoalveolar lavage and mini-bronchoalveolar lavage in the diagnosis of pneumonia in immunocompromised patients. Respiration. 2011;81:229–35.
10. Du Rand IA, Baber PV, Goldring J, Lewis RA, Mandal S, Munavar M, et al. Summary of the British Thoracic Society guidelines for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax. 2011;66:1014–5.
11. Ercan V, Basaranoglu G, Beycan I, Delatticoğlu H, Hamzaoglu NS. Reproducibility of mini-BAL culture results using 10 ml or 20 ml instilled fluid. Intensive Care Med. 2003;29:1856.
12. Mann JM, Altus CS, Webber CA, Smith PR, Muto R, Heurich AE. Nonbronchoscopic lung lavage for diagnosis of opportunistic infection in AIDS. Chest. 1987;91:319–22.
13. Singh C, Rai RK, Azim A, Sinha N, Baronia AK. Mini-bronchoalveolar lavage fluid can be used for biomarker identification in patients with lung injury by employing *1H NMR spectroscopy. Crit Care. 2013;17:430.
14. Colucci G, Domenghetti G, Della Bruna R, Bonilla J, Limoni C, Matthy MA, et al. Comparison of two nonbronchoscopic methods for evaluating inflammation in patients with acute hypoxemic respiratory failure. Crit Care. 2009;13:1–9.
15. Brazilian Ministry of Health, Manual Nacional de vigilância laboratorial da tuberculose e outras micobactérias. Brasília: Brazilian Ministry of Health, 2008. p. 436.
16. Global Laboratory Initiative and Mycobacteriology Laboratory Manual. First ed. Stop TB Partnership. 2014. http://www.stoptb.org/wg/igl/assets/documents/gli_mycobacteriology_lab_manual_web.pdf.
17. Zumla A, Raviglione M, Hafner R, Fordham von Reyn C. Tuberculosis. N Engl J Med. 2013;368:745–55.
18. Erdős R, Görtz K, Raffenberg M, Mauch H, Schmidt-Loosn M, Lodé H. Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. Eur Respir J. 2006;27:1223–8.
19. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998;113:412–20.
20. Fujitani S, Yu VL. Diagnosis of ventilator-associated pneumonia: focus on nonbronchoscopic techniques (nonbronchoscopic bronchoalveolar lavage, including mini-BAL, blind protected specimen brush, and blind bronchial sampling) and endotracheal aspirates. J Intensive Care Med. 2006;21:17–21.
21. Alify MH, Shaheen EA, El-Dahdouh SS, El-Feky HM. Comparison between bronchoalveolar BAL and nonbronchoscopic BAL in patients with VAP. Egypt J Chest Dis Tuberc. 2016;65:113–9.
22. Gaussoin P, Piperno D, Bachmann P, Boyer E, Jean G, Robert D. Comparison of nonbronchoscopic bronchoalveolar lavage to open lung biopsy for the bacteriologic diagnosis of pulmonary infections in mechanically ventilated patients. Intensive Care Med. 1989;15:948–8.
23. Sancho-Chust JN, Ferrejes J, Blanquer J. Mini-Bronchoalveolar lavage (mini-BAL) in the cytological diagnosis of interstitial disorders with acute respiratory failure and mechanical ventilation. Archivos de Bronconeumología. 2010;46:101–2.
24. Boselli E, Breidh L, Djabbaroui S, Guillaume C, Rimmelé T, Gordiner JB, et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med. 2007;33:1519–23.
25. O’Brien JD, Ettinger NA, Shevlin D, Kollef MH. Safety and yield of transbronchial biopsy in mechanically ventilated patients. Crit Care Med. 1997;25:440–6.

26. Bahr NC, Nuwagira E, Evans EE, Cresswell PV, Bystrom PV, Byamukama A, et al. Diagnostic accuracy of Xpert MTB/RIF ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis. 2018;18:68–75.

27. Badal-Faesen S, Firnhaber C, Kendall M, Wu X, Grinsztejn B, Escada R, et al. Impact of larger sputum volume on Xpert® MTB/RIF assay detection of Mycobacterium tuberculosis in smear-negative individuals with suspected tuberculosis. J Clin Med. 2017;6:78.

28. Forbes BA, Hall GA, Miller MB, Novak SM, Rowlinson M-C, Salfinger M, et al. Practice guidelines for clinical microbiology laboratories: mycobacteria. Clin Microbiol Rev. 2018;31:1–66.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.